haloperidol has been researched along with Cognitive Dysfunction in 8 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "None of the three study arms - haloperidol, ketamine, or both drugs combined - was significantly superior to placebo for prevention of postoperative brain dysfunction and delirium (P = 0." | 9.41 | Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. ( Brügger, J; Gysi, B; Hollinger, A; Huber, J; Rentsch, K; Riegger, H; Rüst, CA; Schmid, HR; Siegemund, M; Steiner, L; Surbeck, M; Toft, K; Tran, F, 2021) |
| "Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics." | 5.62 | PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. ( Guimarães, FS; Prado, DDS; Sonego, AB, 2021) |
| "None of the three study arms - haloperidol, ketamine, or both drugs combined - was significantly superior to placebo for prevention of postoperative brain dysfunction and delirium (P = 0." | 5.41 | Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. ( Brügger, J; Gysi, B; Hollinger, A; Huber, J; Rentsch, K; Riegger, H; Rüst, CA; Schmid, HR; Siegemund, M; Steiner, L; Surbeck, M; Toft, K; Tran, F, 2021) |
| "Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics." | 1.62 | PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. ( Guimarães, FS; Prado, DDS; Sonego, AB, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kurimoto, E | 1 |
| Yamada, R | 1 |
| Hirakawa, T | 1 |
| Kimura, H | 1 |
| Liu, J | 1 |
| Yu, D | 1 |
| Li, J | 1 |
| Liao, J | 1 |
| Dong, G | 1 |
| Zhu, W | 1 |
| Wulaer, B | 1 |
| Mizoguchi, H | 1 |
| Sawahata, M | 1 |
| Liu, Y | 1 |
| Kaibuchi, K | 1 |
| Ozaki, N | 1 |
| Nabeshima, T | 1 |
| Nagai, T | 1 |
| Yamada, K | 1 |
| Hollinger, A | 1 |
| Rüst, CA | 1 |
| Riegger, H | 1 |
| Gysi, B | 1 |
| Tran, F | 1 |
| Brügger, J | 1 |
| Huber, J | 1 |
| Toft, K | 1 |
| Surbeck, M | 1 |
| Schmid, HR | 1 |
| Rentsch, K | 1 |
| Steiner, L | 1 |
| Siegemund, M | 1 |
| Sonego, AB | 1 |
| Prado, DDS | 1 |
| Guimarães, FS | 1 |
| Hailwood, JM | 1 |
| Heath, CJ | 1 |
| Phillips, BU | 1 |
| Robbins, TW | 1 |
| Saksida, LM | 1 |
| Bussey, TJ | 1 |
| Nishigaki, A | 1 |
| Kawano, T | 1 |
| Iwata, H | 1 |
| Aoyama, B | 1 |
| Yamanaka, D | 1 |
| Tateiwa, H | 1 |
| Shigematsu-Locatelli, M | 1 |
| Eguchi, S | 1 |
| Locatelli, FM | 1 |
| Yokoyama, M | 1 |
| Park, CH | 1 |
| Park, TW | 1 |
| Yang, JC | 1 |
| Lee, KH | 1 |
| Huang, GB | 1 |
| Tong, Z | 1 |
| Park, MS | 1 |
| Chung, YC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Baden PRIDe Trial - Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial[NCT02433041] | Phase 4 | 200 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for haloperidol and Cognitive Dysfunction
| Article | Year |
|---|---|
Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial.
Topics: Adult; Cognitive Dysfunction; Delirium; Double-Blind Method; Haloperidol; Humans; Ketamine | 2021 |
No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Dizziness; Double-Bli | 2012 |
6 other studies available for haloperidol and Cognitive Dysfunction
| Article | Year |
|---|---|
Therapeutic potential of TAK-071, a muscarinic M
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; CHO Cells; Cognition; Cognitive Dysfunction; C | 2021 |
Comment on:"Ketamine vs haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial".
Topics: Cognitive Dysfunction; Delirium; Double-Blind Method; Haloperidol; Humans; Ketamine | 2022 |
Rho kinase inhibitors ameliorate cognitive impairment in a male mouse model of methamphetamine-induced schizophrenia.
Topics: Animals; Clozapine; Cognitive Dysfunction; Haloperidol; Male; Methamphetamine; Mice; Monomeric GTP-B | 2023 |
PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Behavior, Animal; Cannabidiol; Cognitive Dysf | 2021 |
Blockade of muscarinic acetylcholine receptors facilitates motivated behaviour and rescues a model of antipsychotic-induced amotivation.
Topics: Animals; Antipsychotic Agents; Apathy; Behavior, Animal; Biperiden; Cognitive Dysfunction; Disease M | 2019 |
Acute and long-term effects of haloperidol on surgery-induced neuroinflammation and cognitive deficits in aged rats.
Topics: Animals; Cognition; Cognitive Dysfunction; Cytokines; Delirium; Fear; Haloperidol; Hippocampus; Male | 2019 |